Literature DB >> 22035882

The use of transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a response to the Cochrane Collaboration review of 2011.

Charles E Ray1, Ziv J Haskal, Jean-Francois H Geschwind, Brian S Funaki.   

Abstract

This commentary is written in response to a recent Cochrane Collaboration review published in March 2011 (1). The authors of this commentary would like to express their concerns over the conclusions of the Cochrane review, which state, "There is no firm evidence to support or refute transarterial chemoembolization (TACE) or transarterial embolization (TAE) for patients with unresectable hepatocellular carcinoma (HCC)."
Copyright © 2011 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22035882      PMCID： PMC4332810          DOI： 10.1016/j.jvir.2011.09.014

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN： 1051-0443            Impact factor:   3.464


  38 in total

Review 1.  Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials.

Authors:  Gordon C S Smith; Jill P Pell
Journal:  BMJ       Date:  2003-12-20

Review 2.  Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.

Authors:  J-L Raoul; B Sangro; A Forner; V Mazzaferro; F Piscaglia; L Bolondi; R Lencioni
Journal:  Cancer Treat Rev       Date:  2010-08-17       Impact factor: 12.111

3.  When are randomised trials unnecessary? Picking signal from noise.

Authors:  Paul Glasziou; Iain Chalmers; Michael Rawlins; Peter McCulloch
Journal:  BMJ       Date:  2007-02-17

4.  Comparable survival in patients with unresectable hepatocellular carcinoma treated by radiofrequency ablation or transarterial chemoembolization.

Authors:  Kenneth S Chok; Kelvin K Ng; Ronnie T P Poon; Chi Ming Lam; Jimmy Yuen; Wai Kuen Tso; Sheung Tat Fan
Journal:  Arch Surg       Date:  2006-12

Review 5.  Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma.

Authors:  Roberto S Oliveri; Jørn Wetterslev; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

6.  A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma.

Authors:  G Pelletier; A Roche; O Ink; M L Anciaux; S Derhy; P Rougier; C Lenoir; P Attali; J P Etienne
Journal:  J Hepatol       Date:  1990-09       Impact factor: 25.083

7.  Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial.

Authors:  Masatoshi Akamatsu; Haruhiko Yoshida; Shuntaro Obi; Shinpei Sato; Yukihiro Koike; Tomonori Fujishima; Ryosuke Tateishi; Masatoshi Imamura; Keisuke Hamamura; Takuma Teratani; Shuichiro Shiina; Takashi Ishikawa; Masao Omata
Journal:  Liver Int       Date:  2004-12       Impact factor: 5.828

Review 8.  Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.

Authors:  Calogero Cammà; Filippo Schepis; Ambrogio Orlando; Maddalena Albanese; Lillian Shahied; Franco Trevisani; Pietro Andreone; Antonio Craxì; Mario Cottone
Journal:  Radiology       Date:  2002-07       Impact factor: 11.105

9.  A prospective randomized evaluation of a compound of tegafur and uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization.

Authors:  K Ikeda; S Saitoh; I Koida; A Tsubota; Y Arase; K Chayama; H Kumada
Journal:  Am J Clin Oncol       Date:  1995-06       Impact factor: 2.339

10.  Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study.

Authors:  Johannes Lammer; Katarina Malagari; Thomas Vogl; Frank Pilleul; Alban Denys; Anthony Watkinson; Michael Pitton; Geraldine Sergent; Thomas Pfammatter; Sylvain Terraz; Yves Benhamou; Yves Avajon; Thomas Gruenberger; Maria Pomoni; Herbert Langenberger; Marcus Schuchmann; Jerome Dumortier; Christian Mueller; Patrick Chevallier; Riccardo Lencioni
Journal:  Cardiovasc Intervent Radiol       Date:  2009-11-12       Impact factor: 2.740
View more
  8 in total

1.  Intermediate-stage HCC--upfront resection can be feasible.

Authors:  Alejandro Forner; Marine Gilabert; Jordi Bruix; Jean-Luc Raoul
Journal:  Nat Rev Clin Oncol       Date:  2015-04-07       Impact factor: 66.675

Review 2.  Chemoembolization in patients with hepatocellular carcinoma.

Authors:  Riccardo Lencioni
Journal:  Liver Cancer       Date:  2012-06       Impact factor: 11.740

Review 3.  Treatment of intermediate-stage hepatocellular carcinoma.

Authors:  Alejandro Forner; Marine Gilabert; Jordi Bruix; Jean-Luc Raoul
Journal:  Nat Rev Clin Oncol       Date:  2014-08-05       Impact factor: 66.675

Review 4.  Chemoembolization of hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Pasquale Petruzzi; Laura Crocetti
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

5.  Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma.

Authors:  Riad Salem; Andrew C Gordon; Samdeep Mouli; Ryan Hickey; Joseph Kallini; Ahmed Gabr; Mary F Mulcahy; Talia Baker; Michael Abecassis; Frank H Miller; Vahid Yaghmai; Kent Sato; Kush Desai; Bartley Thornburg; Al B Benson; Alfred Rademaker; Daniel Ganger; Laura Kulik; Robert J Lewandowski
Journal:  Gastroenterology       Date:  2016-08-27       Impact factor: 22.682

Review 6.  Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations.

Authors:  Gino Boily; Jean-Pierre Villeneuve; Luc Lacoursière; Prosanto Chaudhury; Félix Couture; Jean-François Ouellet; Réal Lapointe; Stéphanie Goulet; Normand Gervais
Journal:  HPB (Oxford)       Date:  2014-06-24       Impact factor: 3.647

7.  Transarterial chemoembolization for pain relief in patients with hypervascular painful metastatic spinal tumors refractory to percutaneous vertebroplasty.

Authors:  Yi Chen; Zhiping Yan; Jianhua Wang; Xiaolin Wang; Jiemin Cheng; Gaoquan Gong; Jianjun Luo
Journal:  J Cancer Res Clin Oncol       Date:  2013-05-16       Impact factor: 4.553

8.  A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma.

Authors:  T Meyer; A Kirkwood; M Roughton; S Beare; E Tsochatzis; D Yu; N Davies; E Williams; S P Pereira; D Hochhauser; A Mayer; R Gillmore; J O'Beirne; D Patch; A K Burroughs
Journal:  Br J Cancer       Date:  2013-02-28       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.